Click on a headline to download the news release. For more ACMG News Releases, go to Newsroom then News Releases
Genetics in Medicine Call for Papers
In March of 2011 Genetics in Medicine will be publishing a special issue celebrating the 20th anniversary of the founding of the American College of Medical Genetics in 1991. Be a part of this historic event. For more information about the Genetics in Medicine Call for Papers, click here now. Click here for more information about Genetics in Medicine.
New MOC Part IV Modules Now Available
The ACMG and ABMG have worked together to develop Practice Performance Assessment modules which are one option to satisfy the Maintenance of Certification (MOC) Part IV requirements. These modules are now available by clicking here.
The modules are designed to allow geneticists to demonstrate and evaluate their excellence in practice, identify areas for improvement, and document this improvement. Most are derived from practice guidelines or expert opinion specific to genetic diseases or patient presentations for genetic evaluation. Currently there are 8 modules (listed below) with more on the way.
· Autism Spectrum Disorder · Counseling for Inherited Cancer Risk · Down syndrome · Fragile X syndrome · General Genetics Patient · Genetic Counseling for Preconception or Prenatal Diagnosis · Neurofibromatosis type-1 · Phenylketonuria
The cost is just $25 for ACMG Members and $75 for non-ACMG members.
ACMG Continues to Weigh In Strongly on DTC Genetic Testing
With the announcement of another set of over-the-counter DNA tests being offered at a national drugstore chain, ACMG reinforced its recommendations about Direct-to-Consumer Genetic Testing through a FOX TV television interview, written statements and more.
Statement on Gene Patent Ruling from the ACMG AMERICAN COLLEGE OF MEDICAL GENETICS LAUDS FEDERAL COURT RULING OF GENE PATENTS AS INVALID
March 30, 2010 – Bethesda, MD | The American College of Medical Genetics (ACMG), one of the original plaintiffs in the anti-gene-patenting lawsuit filed in 2009, celebrated the US District Court ruling yesterday that genes are “unpatentable.”
The outcome of this case is likely to have far-reaching positive implications for physicians, researchers and patients. “The invalidation of gene patents will allow patients to get second opinions on test results, encourage quality improvement of current testing, allow researchers to develop new and better methods of testing and decrease costs of laboratory testing. This is a huge, huge victory for better patient care,” said Michael S. Watson, PhD, FACMG, executive director of the ACMG. Click here for more information.
